Form 4 for PCSA Processa Pharmaceuticals, Inc.
Accepted 2024-01-31 00:00:00 ET · period of report 2024-01-30 · accession 0000897069-24-000227 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2024-01-31 | 2024-01-30 | PCSA | Yorke Justin W | Dir | P - Purchase | $2.69 | +8,000 | 31.2K | +34% | +$21.5K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-01-30 | P | A | 8,000 | $2.69 | 31,232 | I By Richland Fund, LLC | — | — | (F1) Effective on January 22, 2024, Processa Pharmaceuticals, Inc. effected a 20 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. |